Cryoport, Inc. (CYRX) Form 8-K — May 4, 2026
Cryoport reported first quarter 2026 revenue of $47.8 million, representing a 16% increase year-over-year, driven primarily by 26% growth in commercial cell and gene therapy revenue to $9.1 million. Based on the strong performance and increased visibility, the company raised its full-year revenue guidance to a range of $192 million to $196 million.
Key figures
- Revenue
- 47800000
- Guidance
- $192 million - $196 million
- Revenue Yoy
- 16%
- Cash Position
- 272912000
- Clinical Trials
- 766
- Commercial CGTs
- 21
- Cash And Short Term Investments
- 403600000
Price after filing
1 day: +19.4%7 days: +29.0%30 days: +61.6%
Close on the filing date to close N calendar days later (from $10.21). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.